<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913716</url>
  </required_header>
  <id_info>
    <org_study_id>VS-6063-106</org_study_id>
    <nct_id>NCT02913716</nct_id>
  </id_info>
  <brief_title>A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects</brief_title>
  <official_title>A Phase I, Open-label Study of the Absorption, Metabolism and Excretion of Defactinib (VS-6063-106) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the mass balance recovery, pharmacokinetics, metabolite profile and
      metabolite identification of defactinib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine amount excreted (Ae)</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine fraction of the dose excreted (Fe)</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine cumulative amount excreted (Cum Ae)</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine cumulative fraction of the dose excreted (Cum Fe)</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine renal clearance (CLr)</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Faeces Ae</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Faeces Fe</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Faeces Cum Ae</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Faeces Cum Fe</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All excreta Ae</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All excreta Fe</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All excreta Cum Ae</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All excreta Cum Fe</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All excreta non-renal clearance (CLnr)</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time at which the analyte is first quantifiable (Tlag)</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing at which Cmax is apparent (Tmax)</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration vs. time curve from time zero extrapolated to last measurable concentration (AUC(0-last))</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration vs. time curve from time zero to infinity (AUC (0-inf))</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of AUC(0-inf) accounted for by extrapolation (AUC%extrap)</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lamdba-z</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent elimination half-life (T1/2)</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance after oral administration (CL/F)</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution after oral administration (Vz/F)</measure>
    <time_frame>Screening to 168h post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Defactinib treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 400 mg [14C]-defactinib, oral suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>defactinib</intervention_name>
    <description>Single oral dose of 400 mg [14C]-defactinib</description>
    <arm_group_label>Defactinib treatment</arm_group_label>
    <other_name>VS-6063</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) 18.0 to 35.0 kg/m2

          -  History (Hx) regular bowel movements

          -  Creatinine clearance &gt;80 mL/min

        Exclusion Criteria:

          -  Hx alcohol abuse in past 2 yrs

          -  Current smoker

          -  Systolic blood pressure (S) or diastolic blood pressure (DBP) above upper limit of
             reference range (age 40-44 &gt;90/140; age 45-65 &gt;90/150)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop Youssoufian</last_name>
    <role>Study Chair</role>
    <affiliation>Verastem, Inc.</affiliation>
  </overall_official>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2016</study_first_submitted>
  <study_first_submitted_qc>September 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

